Rule, Simon - Plymouth University

个人简介

Qualifications Bachelor of Medical Science with Honours 1984 Master of Philosophy 1986 Bachelor of Medicine 1987 Bachelor of Surgery 1987 Professional membership Fellowof the Royal College of Physicians 2000 Fellowof the Royal College of Pathologists of Australasia1994 Fellowof the Royal College of Pathologists 2006 Roles on external bodies MemberNCRN Lymphoma Committee (2000 – 2005, 2006 -) Member Peninsula Comprehensive LocalResearch Network Board (2007 -) Member European Mantle Cell Lymphoma Network (2007 - ) Member Peninsula Medical SchoolR&D committee (2010 -) Associate Medical Director forR&D Derriford Hospital (2010 - ) Member Cancer Research UK ClinicalTrials Advisory Committee (2012 - ) MemberLeukaemia and Lymphoma Research Clinical Trials Committee (2012 -) ChairNCRN Low Grade NHL Committee (2013 -)

研究领域

My clinical research is in non-Hodgkin’s lymphoma(NHL) and new drug development. Over the last 5 years I have been the ChiefInvestigator on 12 National studies and Principal Investigator on over 40 studiesmostly involving NHL. I have a particular interest in mantle cellnon-Hodgkin’s lymphoma (MCL) and am regarded as the leading UK authority in thisdisease. I run a tertiary referral practice and see patients with this diseasereferred from all over the country in a weekly clinic. Within the UK I run allof the MCL trials. Over the last 10 years, 7 multi-centre trials have openedand 4 have recently completed. 4 of these studies were funded by Cancer ResearchUK, 2 others endorsed by CRUK and funded by industry The most recent studiesare coordinated and run through the Plymouth CTU. Two large studies will openin 2015. One is a large bio-bank funded by Leukaemia Lymphoma Researchexploring different disease characteristics of MCL. The other is a largerandomised trial funded by Cancer Research UK looking at the use of ibrutinibas front line therapy in elderly patients with MCL randomised against standardimmuno-chemotherapy. Both of these studies incorporate correlative science witha number of UK collaborators as well as in house laboratory research. Withbiological material stored in almost all patients this will be a uniquerepository for examining biological elements of the disease.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Rule S 2016 'A new standard of care for mantle cell lymphoma?' LANCET ONCOLOGY 17, (1) 5-6 Author Site , DOI Walter HS, Rule SA, Dyer MJS, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV & Honda H 2016 'A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies' BLOOD 127, (4) 411-419 Author Site , DOI Jones GL, Will A, Jackson GH, Webb NJ & Rule S 2016 'Evolving concepts in tumour lysis syndrome management - response to Ayed et al' BRITISH JOURNAL OF HAEMATOLOGY 173, (3) 486-487 Author Site Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J & Bartlett NL 2016 'Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study' LANCET ONCOLOGY 17, (2) 200-211 Author Site , DOI Tucker DL & Rule SA 2016 'Ibrutinib for mantle cell lymphoma' FUTURE ONCOLOGY 12, (4) 477-491 Author Site , DOI Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C & Witzens-Harig M 2016 'Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study' LANCET 387, (10020) 770-778 Author Site , DOI Trneny M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J & Rule S 2016 'Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial' LANCET ONCOLOGY 17, (3) 319-331 Author Site , DOI Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D & Phillips T 2016 'Postibrutinib outcomes in patients with mantle cell lymphoma' BLOOD 127, (12) 1559-1563 Author Site , DOI Rule S, Smith P, Johnson PWM, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S & Kirkwood AA 2016 'The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial' HAEMATOLOGICA 101, (2) 235-240 Author Site , DOI